The CDC Foundation today announced a donation of $50,000 from Walgreens as the first gift to the Foundation’s Ending the HIV Epidemic Fund.

Following last year’s impactful collaboration between Walgreens and the CDC Foundation addressing the Zika outbreak, the two organizations are once again working together to help address another public health challenge—HIV prevention. To help extend the CDC Foundation’s important research and demonstration project, Walgreens made a donation today to help fund the CDC Foundation’s Sustainable Healthcenter Implementation PrEP Pilot (SHIPP) study.

To investigate long-acting PrEP formulations in macaque subjects.

To help CDC increase understanding of the effectiveness of using maternal tenofovir containing combination drug during the second and third trimesters of pregnancy for the prevention of mother-to-child transmission of HIV and HBV in co-infected mothers.

To evaluate a polymer-based in-situ forming implant and its ability to provide long-lasting protection against HIV infection.

To investigate the biocompatibility, the drug release profile and length of prophylactic efficacy of a biodegradable subcutaneous implant containing antiretroviral drug(s), developed by RTI.

To facilitate formation of a Clinical Trials Unit for HIV/AIDS and tuberculosis research to advance therapy and prevention. If the interventions in the clinical trials are determined safe and effective, they will add to the options available to prevent and control these diseases of global significance.